{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:18:26Z","timestamp":1758709106045},"reference-count":59,"publisher":"Impact Journals, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,1,19]]},"DOI":"10.18632\/oncotarget.23204","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T19:48:30Z","timestamp":1513194510000},"page":"5691-5702","source":"Crossref","is-referenced-by-count":9,"title":["Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations"],"prefix":"10.18632","volume":"9","author":[{"given":"William","family":"Bruno","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Martinuzzi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna","family":"Dalmasso","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Andreotti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"Pastorino","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cabiddu","sequence":"additional","affiliation":[{"name":"Pathology Unit, Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Gualco","sequence":"additional","affiliation":[{"name":"Pathology Unit, Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Spagnolo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ballestrero","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Queirolo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Grillo","sequence":"additional","affiliation":[{"name":"Department of Surgical and Diagnostic Sciences, Pathology Unit, University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Mastracci","sequence":"additional","affiliation":[{"name":"Department of Surgical and Diagnostic Sciences, Pathology Unit, University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Ghiorzo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,12,14]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5826\/dpc.0702a01","article-title":"Epidemiological trends in skin cancer","volume":"7","author":"Ioannides","year":"2017","journal-title":"Dermatol Pract Concept"},{"key":"2","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1002\/cncr.30593","article-title":"Somatic driver mutations in melanoma","volume":"123","author":"Tsao","year":"2017","journal-title":"Cancer"},{"key":"3","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1002\/cncr.30435","article-title":"Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma","volume":"123","author":"Rizos","year":"2017","journal-title":"Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"e1006773","DOI":"10.1371\/journal.pgen.1006773","article-title":"Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature","volume":"13","author":"Larsson","year":"2017","journal-title":"PLoS Genet"},{"key":"5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","article-title":"BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site","volume":"24","author":"Bastian","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.cmr.0000222600.73179.f3","article-title":"BRAF and NRAS mutations in melanoma and melanocytic nevi","volume":"16","author":"Gruber","year":"2006","journal-title":"Melanoma Res"},{"key":"7","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","author":"Balu","year":"2015","journal-title":"Cell"},{"key":"8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.21037\/atm.2016.06.07","article-title":"Resistant mechanisms to BRAF inhibitors in melanoma","volume":"4","author":"Mart\u00ednez-Card\u00fas","year":"2016","journal-title":"Ann Transl Med"},{"key":"9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Lawrence","year":"2012","journal-title":"Cell"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.016","article-title":"Selection criteria for genetic assessment of patients with familial melanoma","volume":"61","author":"Debniak","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jaad.2015.09.053","article-title":"Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup","volume":"74","author":"De Giorgi","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/00008390-200412000-00002","article-title":"Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients","volume":"14","author":"Bianchi-Scarr\u00e0","year":"2004","journal-title":"Melanoma Res"},{"key":"13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1755-148X.2008.00512.x","article-title":"CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma","volume":"21","author":"Bianchi Scarr\u00e0","year":"2008","journal-title":"Pigment Cell Melanoma Res"},{"key":"14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/j.1600-0625.2012.01549.x","article-title":"MC1R variation and melanoma risk in relation to host\/clinical and environmental factors in CDKN2A positive and negative melanoma patients","volume":"21","author":"Queirolo","year":"2012","journal-title":"Exp Dermatol"},{"key":"15","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1002\/ijc.25804","article-title":"Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden","volume":"129","author":"Whiteman","year":"2011","journal-title":"Int J Cancer"},{"key":"16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jid.2015.12.035","article-title":"Histologic and Phenotypic Factors and MC1R Status Associated with BRAF(V600E), BRAF(V600K), and NRAS Mutations in a Community-Based Sample of 414 Cutaneous Melanomas","volume":"136","author":"Whiteman","year":"2016","journal-title":"J Invest Dermatol"},{"key":"17","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1038\/jid.2008.67","article-title":"MC1R variants increase risk of melanomas harboring BRAF mutations","volume":"128","author":"Elder","year":"2008","journal-title":"J Invest Dermatol"},{"key":"18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1126\/science.1127515","article-title":"MC1R Germline Variants Confer Risk for BRAF-Mutant Melanoma","volume":"313","author":"Bastian","year":"2006","journal-title":"Science"},{"key":"19","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/jid.2009.410","article-title":"Relationship between germline MC1R variants and BRAF-mutant melanoma in a North Carolina population-based study","volume":"130","author":"Conway","year":"2010","journal-title":"J Invest Dermatol"},{"key":"20","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/bjd.13521","article-title":"BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma","volume":"172","author":"Nagore","year":"2015","journal-title":"Br J Dermatol"},{"key":"21","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1126\/science.aab0015","article-title":"Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer","volume":"348","author":"Chang","year":"2015","journal-title":"Science"},{"key":"22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Kumar","year":"2013","journal-title":"Science"},{"key":"23","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly Recurrent TERT Promoter Mutations in Human Melanoma","volume":"339","author":"Garraway","year":"2013","journal-title":"Science"},{"key":"24","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1038\/ncomms4401","article-title":"Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma","volume":"5","author":"Kumar","year":"2014","journal-title":"Nat Commun"},{"key":"25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00428-015-1784-x","article-title":"Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness","volume":"467","author":"Fontanini","year":"2015","journal-title":"Virchows Arch"},{"key":"26","doi-asserted-by":"publisher","first-page":"dju246","DOI":"10.1093\/jnci\/dju246","article-title":"TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma","volume":"106","author":"Badenas","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00428-014-1608-4","article-title":"Telomerase promoter mutations in cancer: an emerging molecular biomarker?","volume":"465","author":"Soares","year":"2014","journal-title":"Virchows Arch"},{"key":"28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ijc.30042","article-title":"TERT promoter mutations in melanoma survival","volume":"139","author":"Kumar","year":"2016","journal-title":"Int J Cancer"},{"key":"29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Holmes","year":"2017","journal-title":"Nature"},{"key":"30","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/ng.3141","article-title":"Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types","volume":"46","author":"Larsson","year":"2014","journal-title":"Nat Genet"},{"key":"31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/pcmr.12444","article-title":"The CDKN2A\/p16(INK) (4a) 5'UTR sequence and translational regulation: impact of novel variants predisposing to melanoma","volume":"29","author":"Fronza","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"32","doi-asserted-by":"publisher","first-page":"8069","DOI":"10.18632\/oncotarget.14094","article-title":"Heterogeneity and frequency of BRAF mutations in primary melanoma: comparison between molecular methods and immunohistochemistry","volume":"8","author":"Ghiorzo","year":"2017","journal-title":"Oncotarget"},{"key":"33","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/j.1755-148X.2012.00982.x","article-title":"Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study","volume":"25","author":"Wendt","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"34","doi-asserted-by":"publisher","first-page":"50864","DOI":"10.18632\/oncotarget.15140","article-title":"Association between rs2853669 in TERT gene and the risk and prognosis of human cancer: a systematic review and meta-analysis","volume":"8","author":"Cheng","year":"2017","journal-title":"Oncotarget"},{"key":"35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/CMR.0000000000000323","article-title":"Characterization of melanoma susceptibility genes in high-risk patients from Central Italy","volume":"27","author":"Fargnoli","year":"2017","journal-title":"Melanoma Res"},{"key":"36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/modpathol.2014.137","article-title":"Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma","volume":"28","author":"Mandal\u00e0","year":"2015","journal-title":"Mod Pathol"},{"key":"37","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1038\/jid.2014.272","article-title":"Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass","volume":"134","author":"Newton-Bishop","year":"2014","journal-title":"J Invest Dermatol"},{"key":"38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/jid.2013.270","article-title":"Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study","volume":"134","author":"Olsson","year":"2014","journal-title":"J Invest Dermatol"},{"key":"39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/pcmr.12567","article-title":"TERT promoter mutations associate with MC1R variants in melanoma patients","volume":"30","author":"Kumar","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"40","doi-asserted-by":"publisher","first-page":"684","DOI":"10.18632\/oncotarget.6331","article-title":"The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer","volume":"7","author":"Jung","year":"2016","journal-title":"Oncotarget"},{"key":"41","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/ijc.30057","article-title":"The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism","volume":"139","author":"Viana-Pereira","year":"2016","journal-title":"Int J Cancer"},{"key":"42","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/bjc.2014.538","article-title":"TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations","volume":"111","author":"Hoang-Xuan","year":"2014","journal-title":"Br J Cancer"},{"key":"43","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.mce.2014.10.019","article-title":"Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization","volume":"399","author":"Fugazzola","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"44","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis","volume":"164","author":"Kim","year":"2011","journal-title":"Br J Dermatol"},{"key":"45","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00432-016-2322-1","article-title":"Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients","volume":"143","author":"Becker","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"46","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/pcmr.12441","article-title":"TERT promoter mutations associate with fast-growing melanoma","volume":"29","author":"Kumar","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"47","doi-asserted-by":"publisher","first-page":"45704","DOI":"10.1038\/srep45704","article-title":"Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma","volume":"7","author":"Bahrami","year":"2017","journal-title":"Sci Rep"},{"key":"48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.humpath.2003.08.017","article-title":"Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients","volume":"35","author":"Bianchi-Scarr\u00e0","year":"2004","journal-title":"Hum Pathol"},{"key":"49","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jclinpath-2013-202127","article-title":"Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker","volume":"67","author":"Steiniche","year":"2014","journal-title":"J Clin Pathol"},{"key":"50","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cca.2005.10.029","article-title":"Novel biomarkers in malignant melanoma","volume":"367","author":"Bosserhoff","year":"2006","journal-title":"Clin Chim Acta"},{"key":"51","first-page":"1845","article-title":"Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma","volume":"6","author":"Akslen","year":"2000","journal-title":"Clin Cancer Res"},{"key":"52","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s12020-015-0720-9","article-title":"A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer","volume":"53","author":"Mastracci","year":"2016","journal-title":"Endocrine"},{"key":"53","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1093\/hmg\/ddl199","article-title":"Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma","volume":"15","author":"Queirolo","year":"2006","journal-title":"Hum Mol Genet"},{"key":"54","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jaad.2009.03.039","article-title":"Clinical genetic testing for familial melanoma in Italy: a cooperative study","volume":"61","author":"Nasti","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"55","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/pcmr.12047","article-title":"Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history","volume":"26","author":"Bianchi Scarr\u00e0","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"56","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00418-015-1316-4","article-title":"Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections","volume":"144","author":"Mastracci","year":"2015","journal-title":"Histochem Cell Biol"},{"key":"57","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00418-017-1596-y","article-title":"Quality control in diagnostic immunohistochemistry: integrated on-slide positive controls","volume":"148","author":"Grillo","year":"2017","journal-title":"Histochem Cell Biol"},{"key":"58","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.humpath.2015.04.012","article-title":"Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma","volume":"46","author":"Hwu","year":"2015","journal-title":"Hum Pathol"},{"key":"59","unstructured":"The R Project for Statistical Computing. Accessed 2017 Oct 12. Available from https:\/\/www.r-project.org\/."}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T11:10:11Z","timestamp":1589022611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,1,19]]}},"alternative-id":["23204","29464027"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.23204","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]}}}